Studies on risk of leprosy relapses in China: relapses after treatment with ...

Title:
Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy

Author:
Chen X, Li W, Jiang C, Zhu Z, Ye G

Address:
National Center for STD and Leprosy Control, Institute of Dermatology, Chinese Academy of Medical Sciences, 12 Jiangwangmiao Road, Nanjing 210042, P. R. China

Source:
International Journal of Leprosy and Other Mycobacterial Diseases, 1999 (67): 379-87

Abstract:
OBJECTIVE: To investigate the profiles of leprosy relapses after treatment with WHO recommended multidrug therapy in China. Methods: Based upon the data from the Chinese National System for Leprosy Surveillance, this paper reports on the relapses in 47,276 leprosy patients cured by or released from WHO-recommended multidrug therapy (WHO/MDT). RESULTS: The overall relapse rate was 0.73/1000 patient-years (PY). There was a statistically significant difference in the relapse rates of WHO/MDT-MB (0.61/1000 PY) and WHO/MDT-PB (1.04/1000 PY) (chi 2 = 15.7, p < 0.01) patients. For multibacillary (MB) patients, the relapse rate in patients treated with fixed-duration MDT (0.56/1000 PY) was comparable with that in patients treated with MDT until skin-smear negativity (0.73/1000 PY) (chi 2 = 2.20, p > 0.05). CONCLUSION: Our present study suggests that fixed-duration MDT is a cost-effective regimen for the treatment of leprosy in China. The present results also show that relapse of leprosy is acceptably low and has not yet become a serious clinical or public health problem but, based upon the incubation of relapse in MDT patients, it is necessary to encourage annual follow up for at least 5 years for paucibacillary (PB) and 10 years for MB patients after being released from WHO/MDT.

Key words: Leprosy; Multidrug therapy; Relapse; China

Language: English